CN114423758B - 抗细菌化合物 - Google Patents
抗细菌化合物 Download PDFInfo
- Publication number
- CN114423758B CN114423758B CN202080064727.XA CN202080064727A CN114423758B CN 114423758 B CN114423758 B CN 114423758B CN 202080064727 A CN202080064727 A CN 202080064727A CN 114423758 B CN114423758 B CN 114423758B
- Authority
- CN
- China
- Prior art keywords
- compound
- mmol
- alkyl
- give
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19197183.7 | 2019-09-13 | ||
| EP19197183 | 2019-09-13 | ||
| PCT/EP2020/075458 WO2021048342A1 (en) | 2019-09-13 | 2020-09-11 | Antibacterial compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114423758A CN114423758A (zh) | 2022-04-29 |
| CN114423758B true CN114423758B (zh) | 2025-05-27 |
Family
ID=67956507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080064727.XA Active CN114423758B (zh) | 2019-09-13 | 2020-09-11 | 抗细菌化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220340564A1 (https=) |
| EP (1) | EP4028399B1 (https=) |
| JP (1) | JP7680433B2 (https=) |
| CN (1) | CN114423758B (https=) |
| AU (1) | AU2020346370B2 (https=) |
| BR (1) | BR112022003799A2 (https=) |
| CA (1) | CA3149868A1 (https=) |
| ES (1) | ES2978573T3 (https=) |
| MX (1) | MX2022003037A (https=) |
| WO (1) | WO2021048342A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108348510B (zh) | 2015-09-17 | 2022-01-04 | 圣母大学 | 针对分枝杆菌感染有用的含有苄胺的杂环化合物以及组合物 |
| EP4308239A1 (en) * | 2021-03-16 | 2024-01-24 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| IL312366A (en) | 2021-10-28 | 2024-06-01 | Janssen Sciences Ireland Unlimited Co | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| EP4296674A1 (en) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025017047A1 (en) | 2023-07-18 | 2025-01-23 | Janssen Pharmaceutica Nv | Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104718213A (zh) * | 2012-07-18 | 2015-06-17 | 圣母大学 | 5,5-杂芳族抗感染化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1527050T3 (da) | 2002-07-25 | 2010-07-19 | Janssen Pharmaceutica Nv | Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer |
| CA2793086C (en) | 2010-03-18 | 2018-08-21 | Institut Pasteur Korea | Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| EP2751104B1 (en) | 2011-09-01 | 2019-09-25 | Novartis AG | Compounds and compositions as c-kit kinase inhibitors |
| DK3027615T3 (da) | 2013-08-02 | 2021-10-25 | Pasteur Institut Korea | Antiinfektionsforbindelser |
| CN105524058B (zh) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| BR112017028318B1 (pt) | 2015-07-02 | 2024-02-20 | Janssen Sciences Ireland Uc | Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação |
| CN108348510B (zh) * | 2015-09-17 | 2022-01-04 | 圣母大学 | 针对分枝杆菌感染有用的含有苄胺的杂环化合物以及组合物 |
| BR112018076126A2 (pt) | 2016-06-16 | 2019-03-26 | Janssen Sciences Ireland Unlimited Company | compostos heterocíclicos como antibacterianos |
| MX2018015657A (es) * | 2016-06-16 | 2019-03-14 | Janssen Sciences Ireland Unlimited Co | Compuestos heterociclico como antibacterianos. |
| WO2018084809A1 (en) * | 2016-11-02 | 2018-05-11 | Nanyang Technological University | Methods for the treatment or prevention of mycobacterial infections |
-
2020
- 2020-09-11 WO PCT/EP2020/075458 patent/WO2021048342A1/en not_active Ceased
- 2020-09-11 US US17/639,963 patent/US20220340564A1/en active Pending
- 2020-09-11 CN CN202080064727.XA patent/CN114423758B/zh active Active
- 2020-09-11 BR BR112022003799A patent/BR112022003799A2/pt unknown
- 2020-09-11 AU AU2020346370A patent/AU2020346370B2/en active Active
- 2020-09-11 CA CA3149868A patent/CA3149868A1/en active Pending
- 2020-09-11 EP EP20776062.0A patent/EP4028399B1/en active Active
- 2020-09-11 JP JP2022516117A patent/JP7680433B2/ja active Active
- 2020-09-11 ES ES20776062T patent/ES2978573T3/es active Active
- 2020-09-11 MX MX2022003037A patent/MX2022003037A/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104718213A (zh) * | 2012-07-18 | 2015-06-17 | 圣母大学 | 5,5-杂芳族抗感染化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114423758A (zh) | 2022-04-29 |
| KR20220062564A (ko) | 2022-05-17 |
| MX2022003037A (es) | 2022-04-07 |
| EP4028399C0 (en) | 2024-02-14 |
| WO2021048342A1 (en) | 2021-03-18 |
| EP4028399A1 (en) | 2022-07-20 |
| US20220340564A1 (en) | 2022-10-27 |
| JP7680433B2 (ja) | 2025-05-20 |
| AU2020346370B2 (en) | 2026-02-12 |
| JP2022548247A (ja) | 2022-11-17 |
| ES2978573T3 (es) | 2024-09-16 |
| BR112022003799A2 (pt) | 2022-05-24 |
| EP4028399B1 (en) | 2024-02-14 |
| AU2020346370A1 (en) | 2022-05-05 |
| CA3149868A1 (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114423758B (zh) | 抗细菌化合物 | |
| JP2026048784A (ja) | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 | |
| CN107530329B (zh) | 用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物 | |
| TW202115065A (zh) | Kras突變蛋白抑制劑 | |
| CN107148417A (zh) | 苯并氮杂*磺酰胺化合物 | |
| EP3173412A1 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| KR20140059164A (ko) | 트라이사이클릭 자이라제 억제제 | |
| CN117440958A (zh) | 抗菌化合物 | |
| CN115667226A (zh) | 作为egfr抑制剂的三环化合物 | |
| CN117580843A (zh) | 抗菌化合物 | |
| CN117396475A (zh) | 抗菌化合物 | |
| WO2022032484A1 (zh) | 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用 | |
| KR102955654B1 (ko) | 항균 화합물 | |
| HK40073265A (zh) | 抗细菌化合物 | |
| HK40080567A (en) | Antibacterial compounds | |
| HK40080567B (en) | Antibacterial compounds | |
| HK40073265B (zh) | 抗细菌化合物 | |
| TW202543616A (zh) | Stat6抑制劑及其使用方法 | |
| HK40078921A (en) | Tricyclic compounds as egfr inhibitors | |
| HK40004907A (zh) | 作为抗细菌剂的杂环化合物 | |
| HK1243701B (zh) | 苯并氮杂䓬磺酰胺化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40073265 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |